Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries.
The investigators tested whether abciximab-coated stents prevent neointimal hyperplasia (NIH) formation in coronary de novo lesions. Abciximab-coated stents were compared with control stents. All patients underwent follow-up coronary angiography and intravascular ultrasound (IVUS). All stents were successfully deployed, and patients were discharged home without clinical events. At follow-up coronary angiography, the restenosis rate and late loss were 14% and 0.33 +/- 0.28 mm in the abciximab-coated stent group and 28.6% and 0.64 +/- 0.32 mm in the control stent group (p = 0.099 and p = 0.014, respectively). At follow-up IVUS, the intrastent luminal area and intrastent NIH area were 5.7 +/- 1.6 and 2.0 +/- 1.6 mm(2), respectively, in the abciximab-coated stent group and 4.2 +/- 0.8 and 3.4 +/- 1.7 mm(2), respectively, in the control stent group (p = 0.001 and p = 0.001, respectively). Abciximab-coated stents are feasible and significantly inhibit NIH, with potential therapeutic benefit in preventing stent restenosis.
The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Science, Gwangju, Korea.
Young Joon
YJ
Hong
Myung Ho
MH
Jeong
Weon
W
Kim
Sang Yup
SY
Lim
Sang Hyun
SH
Lee
Seo Na
SN
Hong
Ju Han
JH
Kim
Young Keun
YK
Ahn
Jeong Gwan
JG
Cho
Jong Chun
JC
Park
Dong Lyun
DL
Cho
Hoon
H
Kim
Jung Chaee
JC
Kang
D000077284:Abciximab; D000208:Acute Disease; D000789:Angina, Unstable / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000925:Anticoagulants / Q000008:administration & dosage*; D003331:Coronary Vessels / Q000473:pathology*; D004337:Drug Carriers; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia / Q000517:prevention & control; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D011446:Prospective Studies; D015607:Stents; D013577:Syndrome; D017539:Tunica Intima / Q000473:pathology*
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D004337:Drug Carriers; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab